Chief Executive Officer, Co-founder
Rudy is a French Computer Scientist. He graduated from Imperial College London with a degree in Computing Engineering during which he worked under the supervision of Dr. Aldo Faisal in the bioengineering department. Passionate about health, he then moved to Tel Aviv to work at the Israeli medtech company Healthy.io focused on remote diagnosis as a software engineer and then as a Product Manager where he helped the team grow from 4 to 20 under 12 months. That same year, he set up and curated the first TEDMED event in London. He then pursued a course on impactful problem solving as the youngest graduate at Singularity University at NASA Ames. At Mendelian, Rudy is in charge of the product design and manages the company's day-to-day business.
Executive Chairman, Co-founder
Fran is a Spanish Industrial Engineer and business professional who started his career in Sales and Marketing Consulting in Pharma. After completing his MBA at Insead, he enrolled in the Corporate Finance practice of a global strategy firm and conducted engagements across Europe for both industrial conglomerates and private equity investors. He then jumped at the opportunity to manage the Administration function at the Spanish start-up of a large UK car insurer, which enticed him to kickstart his own entrepreneurial journey. Over the past decade, Fran has been involved as a founder or seed investor in multiple successful B2C and B2B ventures, leading functions as diverse as Marketing, Technology and Governance. Fran met his Mendelian co-founders at Singularity University's GSP program in 2014.
Dr Ignacio Hernandez Medrano
Clinical Advisor, Co-Founder
Dr Ignacio was awarded "Digital health personality of 2017" in Spain. He is a Spanish practicing Neurologist with strong interest in Genetics and Healthcare systemic changes. His background comprises Healthcare Management and Public Health Administration in the biggest health institutions in Spain. Nacho was Head of Strategy of the Ramon y Cajal Health Research Institute. He joined Mendelian as Chief Scientist while graduating from the GSP program at Singularity University at NASA Ames in 2014.
Dr Will Evans
Dr Will Evans is the clinical lead at Mendelian and a practicing GP and academic. Will graduated from the University of Leeds MBChB in 2002 and works as a GP in Leeds. He completed an MSc in Genomic Medicine with distinction from the University of Manchester in 2018. Will holds an NIHR in practice fellowship award (Oct 2018 – April 2021) and works part time with the PRISM research group at the University of Nottingham. His research interests involve personalised medicine, rare diseases, genomics in Primary Care and large database analysis. Will’s eldest son Sam has Niemann-Pick type C, an ultra rare metabolic disease and Will is the current chairman of the board of NPUK the disease’s national charity.
Dr Orlando Buendia
Dr Orlando Buendia is a Peruvian Medical Doctor. He graduated from Universidad Científica del Sur. He specialized in Internal Medicine in the US at MedStar Washington Hospital Center. Alongside he founded a real estate company called DEPTO, an entrepreneur business based on building and renting 26 self-owned micro-apartments targeting millennials living preferences in Lima - Peru. DEPTO is the first business model in PERU for build-to-rent apartment blocks instead of selling. Motivated from that entrepreneurial experience, he pursued an MBA at Manchester Business School, and an MPH focused in Health Economics at London School of Hygiene and Tropical Medicine. During this period, he discovered the potential of digital health into healthcare systems.
Dr Peter Fish
Dr Peter Fish is a South African medical doctor with a BSc Honours degree in Human Genetics and an MBA. He has founded and managed a number of IT-based companies. Peter focuses on medical genomics and assists Mendelian with both the medical and business development aspects. He is also involved in a translational genomics project at the Wellcome Trust Sanger Institute in Cambridge, UK within the COSMIC oncology division.
Nicolas Aussel obtained a Master degree in Computer Science from the French engineering school Télécom SudParis. He was then hired as a research engineer by the Munich branch of the aerospace manufacturer Safran to work on Data Science applications. From 2016 to 2019, Safran funded his Ph.D. preparation in applied Machine Learning at Université Paris-Saclay on the topic of Predictive Maintenance, defended in June 2019. He was awarded the Safran Innovation of the Year Award 2019 in the service category for his work on recommender systems. He joined Mendelian in November 2019 as a research associate to develop new Artificial Intelligence methods to help in rare disease screening.
Renate is a medical student from Latvia with a degree in political science from the London School of Economics. She started her career as a political risk analyst at AKE International and S-RM Intelligence and Risk Consulting to help clients navigate economic, political, and security risks in the Eurasia region. After gaining an in-depth experience in political risk analysis, she decided to switch her career to one that would be related to medicine. In 2018 she enrolled in medical school at Riga Stradiņs University. Before joining Mendelian, she gained experience in the hematology-oncology department at the Children's hospital in Latvia.
After graduating with a degree in Computer Science from the University of Bristol, Tim pursued a career in Data Analytics and Artificial Intelligence where he helped build out the data science capability of well known UK brands such as Marks & Spencer and Holland & Barrett. At Mendelian, Tim builds out the company’s secure data pipelines and is active in product development and research.
Head of Operations
After graduating from Newcastle Business School with a Master’s in Finance, Holly began her career in healthcare, working with both private and NHS organisations. In 2017, Holly moved to London where she began working in start-ups, specifically within digital healthcare and artificial intelligence. Holly has recently graduated with an Executive MBA, with her final thesis exploring how digital healthcare can change the economic cost of delayed treatment. Holly is in charge of the day-to-day operations for Mendelian.
Raid has extensive experience in building modern, compliant backend systems and has helped several organisations in regulated sectors, such as meteorological science, financial services, e-commerce and rail & aerospace engineering migrate to and leverage public cloud services. Raid works on Mendelian’s data pipelines and writes software to enable doctors, clinicians and researchers enact the company’s mission.
Sneha is a health economist at Mendelian where her role includes the quantification of cost and resource impact of undiagnosed rare diseases on health systems. She has worked with big pharmaceutical companies such as Amgen, UCB and Dr. Falk and helped in delivering clinical and economic evidence for Health Technology Assessments. She holds a Master’s in Global Health and Policy from Queen Mary University. Prior to pursuing a career in Health Economics, she worked as a dentist in India.
After entering a French engineering school, Dan chose to specialize in data science and artificial intelligence. At Mendelian, Dan is completing his final year internship, where he works closely with Nicolas on machine learning projects and contributes to the research and development of the company.
Head of Strategy
James is a dual qualified Engineer and Surgeon with a specific interest in digital health and analytics. After 4 years in the NHS training as an ENT surgeon he left to help improve the wider health system. First as a management consultant where he helped develop strategy for healthcare regions but now as Head of Strategy at Mendelian. He is in charge of ensuring that Mendelian provides the maximum value to the wider health economy while also scaling efficiently and sustainably.